@Biohazard3737 Is there an analysis on years behind? Would imagine being second entrant 9 mon behind is different from 4 years behind.

@drug_smolecules @Majzner_Lab @BertrandBio @MSubklewe @bradloncar @ByMadeleineA @JacobPlieth @Prof_Oak_ Interesting. Conversely why didn’t they develop CD19 for oncology instead of CD20?

@bio_clouseau Developing back up means their current B7H3 must be best in class

@Bakery_bros I get SGEN is expensive but it has cash flow which offers more strategic value. You think BT8009 can show superiority vs EV in H2H in mUC? I think 5% PoS.

RT @mendesthiagob: ❗️SGLT2i were described a long time ago. ✅They are now popular drugs to treat type 2 diabetes, heart failure, and chron…

@timxqi That’s a nice looking tool. What did you use to generate?

@retailbiotech

@KRHornberger Would PD effect be twice as long tho if coming off twice as slow?

@KRHornberger Thanks you. Why is it less likely to be true for small molecules?

@KRHornberger Do you know any good resource for building foundational PK analysis on Excel? Or any good softwares without tons of $$$?

@JacobPlieth PR is still very vague, likely intentionally. It didn't specifically state that RSBQ-AUC was aligned with MHRA to be the regulatory endpoint. 🤡

@bigpharmaguy Meaning increase or decrease….?

@bigpharmaguy For the chemo arm, is PFS expected to increase or decrease for post CDK4/6 vs no CDK4/6?

@adamfeuerstein Also it’s “RSBQ AUC” not even real RSBQ

@adamfeuerstein $AVXL also didn’t report RSBQ which probably failed. Regulators are not going to care about “RSBQ AUC”

@Biohazard3737 Always a circus show with $SRPT

@tigitation Which big biopharma doesn’t have a TIGIT yet?

@jaybradner Wasn’t branaplam discovered for SMN2 in SMA?

@retailbiotech